Literature DB >> 2786071

Temporal trends of human immunodeficiency virus type 1 (HIV-1) infection among inmates entering a statewide prison system, 1985-1987.

D Vlahov1, F Brewer, A Muñoz, D Hall, E Taylor, B F Polk.   

Abstract

Acquired immune deficiency syndrome (AIDS) became the leading cause of death among Maryland State prisoners in 1985. To identify the prevalence, risk factors, and temporal trends for infection with the human immunodeficiency virus type 1 (HIV-1) in the statewide prison system, excess sera were obtained from incoming male inmates during specified periods between April and June 1985, 1986, and 1987. Correctional medical personnel also provided demographic variables of age, race, offense category, sentence, jurisidiction, and an indicator of intravenous drug use. Once rendered anonymous, specimens were assayed for antibody to HIV-1, using ELISA and Western blot techniques. For data from April to June 1985, 1986, and 1987, the crude prevalence of anti-HIV-1 was 7.1, 7.7, and 7.0%, respectively. Although one-third of incoming inmates were identified as intravenous drug users (IVDUs), the drug use variable was missing for 70% of the 1985 sample, and 40% of the 1986 sample. Several strategies were used to examined temporal trends in the context of missing data. Univariate analyses suggested no substantial change over time for either HIV-1 seroprevalence or risk of infection among IVDUs.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2786071

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr (1988)        ISSN: 0894-9255


  17 in total

Review 1.  Social determinants and the health of drug users: socioeconomic status, homelessness, and incarceration.

Authors:  Sandro Galea; David Vlahov
Journal:  Public Health Rep       Date:  2002       Impact factor: 2.792

2.  Prevalence and incidence of HIV, hepatitis B virus, and hepatitis C virus infections among males in Rhode Island prisons.

Authors:  Grace E Macalino; David Vlahov; Stephanie Sanford-Colby; Sarju Patel; Keith Sabin; Christopher Salas; Josiah D Rich
Journal:  Am J Public Health       Date:  2004-07       Impact factor: 9.308

3.  Death in prison: changing mortality patterns among male prisoners in Maryland, 1979-87.

Authors:  M E Salive; G S Smith; T F Brewer
Journal:  Am J Public Health       Date:  1990-12       Impact factor: 9.308

4.  From corrections to communities as an HIV priority.

Authors:  David Vlahov; Sara Putnam
Journal:  J Urban Health       Date:  2006-05       Impact factor: 3.671

5.  Implementing a routine, voluntary HIV testing program in a Massachusetts county prison.

Authors:  Rebecca V Liddicoat; Hui Zheng; Jeanne Internicola; Barbara G Werner; Arthur Kazianis; Yoav Golan; Eric P Rubinstein; Kenneth A Freedberg; Rochelle P Walensky
Journal:  J Urban Health       Date:  2006-11       Impact factor: 3.671

6.  Using a jail-based survey to monitor HIV and risk behaviors among Seattle area injection drug users.

Authors:  H Thiede; M Romero; K Bordelon; H Hagan; C S Murrill
Journal:  J Urban Health       Date:  2001-06       Impact factor: 3.671

7.  Characteristics and trends of newly identified HIV infections among incarcerated populations: CDC HIV voluntary counseling, testing, and referral system, 1992-1998.

Authors:  K M Sabin; R L Frey; R Horsley; S M Greby
Journal:  J Urban Health       Date:  2001-06       Impact factor: 3.671

8.  Coinfection with tuberculosis and HIV-1 in male prison inmates.

Authors:  M E Salive; D Vlahov; T F Brewer
Journal:  Public Health Rep       Date:  1990 May-Jun       Impact factor: 2.792

9.  Prevalence and incidence of hepatitis C virus infection among male prison inmates in Maryland.

Authors:  D Vlahov; K E Nelson; T C Quinn; N Kendig
Journal:  Eur J Epidemiol       Date:  1993-09       Impact factor: 8.082

10.  HIV infection in the Women's Jail, Orange County, California, 1985 through 1991.

Authors:  G A Gellert; R M Maxwell; K V Higgins; T Pendergast; N Wilker
Journal:  Am J Public Health       Date:  1993-10       Impact factor: 9.308

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.